Full-year loss of $1.68 per share (excluding special items but
including stock-based compensation expense) were narrower than the
Zacks Consensus Estimate of a loss of $2.83 and the year-ago loss
of $3.07 per share.

Total revenue in the reported quarter climbed to $202.1 million
from $25.0 million in the comparable quarter of 2010. We note,
however, that revenue in the reported quarter included one time
royalty revenue of $125 million related to sale of its royalty
interest in
Merck, Inc.'s
(
MRK
) hepatitis C product Victrelis.

Excluding this one-time revenue, Dendreon recorded revenues of
$77 million. The Zacks Consensus Estimate was at $113 million.
Full-year revenues at $341.6 million were above the year-ago
revenues of $48.1 million. The Zacks Consensus full-year estimate
was at $259 million.

Quarter in Details

Dendreon reported net Provenge revenue of $77.0 million in the
fourth quarter up from $25.0 million in the comparable quarter of
2010. However, we note that earlier on January 5, 2012, during
pre-announcement of fourth quarter results, management declared
gross product revenue of approximately $82 million.

Research & development (R&D) expenses were $18 million,
reflecting a year-over-year increase of 50%. Selling, general &
administrative (SG&A) expenses for the fourth quarter decreased
11.3% to $76 million.

Provenge Update

For the full year 2011, Dendreon reported net Provenge revenue
of $214 million. Full-year sales of Provenge was, however, well
below the company's original forecast, in a band of $350 million -
$400 million, which was withdrawn last year on dismal performance
of the vaccine.

Despite a favorable reimbursement environment for the vaccine,
Dendreon faced tough times in 2011 as Provenge sales failed to live
up to the expectations of the management and the investors.
Provenge's high cost density had been eluding physician acceptance
of the vaccine. Other problems which were affecting the sales of
the vaccine included lack of easy access to Provenge and inability
on the part of physicians to identify eligible patients for
Provenge treatment.

According to management awareness gradually improves on the
favorable reimbursement environment. The physicians are more
comfortable with prescribing Provenge as the average time to
payment for physicians has come down to less than 30 days.

Moreover, management pointed out that out of pocket expenses
were negligible for almost 75% of the patients on Provenge
treatment. Dendreon reported that the number of centers where
patients can be treated with Provenge increased from 425 at the end
of the third quarter 2011 to 590 centers at the end of 2011. So
far, the company has added another 80 sites in 2012.

Management announced that the European Medicines Agency (EMA)
accepted the marketing authorization application (
MAA
) for Provenge, submitted by the company in January 2012.

Outlook

Dendreon expects to post modest quarter-over-quarter growth in
2012.

In the first quarter 2012 the company expects to see moderate
single digit growth in Provenge sales. The company said the there
was some pull through of January sales in December, of
approximately $2 million to $3 million, as patients want have their
treatment completed by the year end holidays.

The company expects to achieve cash breakeven at $125 million
net revenue each quarter or annual net revenue to be $500 million.
At this level of net revenues, the company expects to reduce the
cost of goods sold to 50% from the current 70% range. The company
expects to reduce cost of goods sold further to 20% - 30% by
2014.

The company expects 2012 R&D expenses to be approximately
$100 million. The expenses are expected to be higher in the first
two quarters than later in the year. Fourth quarter R&D
expenditure is expected to be around $20 million.

In 2012, SG&A expenses are expected to decrease throughout
the year, primarily as a result of a reduction in non-cash deferred
compensation. Fourth quarter SG&A expenses are expected to be
around $70 million.

Our Recommendation

We currently have a Neutral recommendation on Dendreon. The
stock carries a Zacks #3 Rank (Hold rating) in the short run.

The successful commercialization of Provenge is crucial for the
financial performance of Dendreon as it can drive the company to
profitability. Though we are concerned about the expected
discouraging growth of Provenge in the first quarter 2012 and
prefer to remain on the sidelines until we get better visibility on
whether the improvement in Provenge's sales is sustainable.

We are also concerned about the competition faced by Provenge
from
Johnson & Johnson
(
JNJ
) Zytiga which was launched in the second quarter of 2011 and is
doing reasonably well. Moreover,
Medivation's
(
MDVN
) pipeline candidate, MDV3100, generated positive data in the
beginning of 2012 which showed that the AFFIRM study met all the
primary and secondary endpoints with statistical significance.
MDV3100, if approved, could pose stiff competition to Provenge.

In the long run, we remain concerned about the company's
dependence on Provenge and the lack of a decent pipeline. We
believe Dendreon has little to fall back on if Provenge further
belies expectations.

Please note that once you make your selection, it will apply to all future visits to NASDAQ.com.
If, at any time, you are interested in reverting to our default settings, please select Default Setting above.

If you have any questions or encounter any issues in changing your default settings, please email isfeedback@nasdaq.com.

Please confirm your selection:

You have selected to change your default setting for the Quote Search. This will now be your default target page;
unless you change your configuration again, or you delete your
cookies. Are you sure you want to change your settings?